GLP-1 drugs and addiction, dementia, sleep apnea: what the evidence actually says

What did @dr.pinkbrain actually say?

The creator claims semaglutide (Ozempic/Wegovy) is headed far beyond weight loss and diabetes, citing a study showing a "40 to 70% decrease in the development of Alzheimer's dementia" in type 2 diabetes patients. They also say it may treat sleep apnea, obesity hypoventilation syndrome, food addiction, shopping addiction, nicotine addiction, recreational drug use, and alcohol use disorder. They mention seeing "private research that has not been publicly published yet" and frame these uses as an emerging wave that will change the stigma around GLP-1 drugs.

To be clear: some of these claims have real, peer-reviewed support. Others are early-stage or frankly speculative. The creator bundles them together without distinguishing between FDA-approved uses, promising trial data, and loose observational findings, and that matters a lot when people are making health decisions.

Does the science back this up?

The dementia claim is the strongest one here, but it is still observational data, not a clinical trial. The sleep apnea claim has actual trial support. The addiction claims are real signals in the literature, but most are early-phase or based on retrospective data.

On dementia: a large 2024 study by Wang et al. published in Alzheimer's and Dementia analyzed over one million patients with type 2 diabetes and found semaglutide users had significantly lower rates of Alzheimer's diagnosis compared to users of other diabetes medications. The effect sizes were notable. But this is a retrospective cohort study, meaning it cannot prove causation. Patients prescribed semaglutide may differ in income, access to care, and baseline health from those on older drugs.

On sleep apnea: the SURMOUNT-OSA trial (Malhotra et al., 2024, New England Journal of Medicine) tested tirzepatide, not semaglutide, in patients with moderate-to-severe obstructive sleep apnea and obesity. It showed meaningful reductions in apnea-hypopnea index scores. The FDA approved tirzepatide for obstructive sleep apnea in June 2024. The creator attributes this to Ozempic/Wegovy specifically, which is an error worth noting.

On addiction: there is legitimate early-stage research. A 2023 analysis by Klausen et al. in eClinicalMedicine found GLP-1 receptor agonist users had lower rates of alcohol use disorder diagnoses. Animal studies support a dopamine-reward mechanism. But there are no large randomized controlled trials in humans yet for nicotine, shopping, or recreational drug addiction specifically.

What did they get wrong (or right)?

The creator gets partial credit on dementia and sleep apnea but makes two notable errors. First, the sleep apnea approval is for tirzepatide (Zepbound), not semaglutide. These are different drugs. Conflating them is a meaningful mistake when patients are making treatment inquiries. Second, citing "private research that has not been publicly published yet" as supporting evidence is not how science works. Unpublished data from a hallway conversation during a rotation is not evidence anyone can evaluate.

What they got right: the general direction of the research is real. GLP-1 receptors exist throughout the brain, including in reward-related regions, and the idea that these drugs affect more than just appetite is scientifically credible. The dementia association study they reference does appear to be the Wang et al. 2024 paper, and the figures they cite (40 to 70%) roughly match published effect estimates. That is more specificity than most TikTok health content manages.

What they got wrong beyond the tirzepatide error: framing all of this as near-certain future treatments understates how far most of these indications are from clinical use. "Uncontrollable shopping addiction" as a GLP-1 indication is based on a handful of case reports and animal studies. Presenting it alongside FDA-adjacent sleep apnea data without distinction does viewers a disservice.

What should you actually know?

If you are considering a GLP-1 medication, the evidence base matters for the specific condition you have. Here is where things actually stand as of mid-2025.

• Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Those indications have robust trial data behind them.
• Tirzepatide (Zepbound) received FDA approval in 2024 for obstructive sleep apnea in adults with obesity. This is real and significant, but it is a different drug from Ozempic.
• The dementia association data is intriguing and worth watching, but no regulatory body has approved any GLP-1 drug to prevent or treat Alzheimer's disease. Observational associations are not the same as proven effects.
• Addiction research is early-stage. There are signals in the data, but no approved indication and no clinical protocol for using these drugs to treat nicotine or alcohol use disorder outside of a research setting.
• If you want to explore GLP-1 therapy, talk to a licensed clinician about your specific situation, not a TikTok video citing unpublished hallway conversations.